LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

July 31, 2013

Conditions
Nasopharyngeal Carcinoma
Interventions
BIOLOGICAL

Genetically modified CTLs

"LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x10\^8 cells/m2"

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00516087 - LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) | Biotech Hunter | Biotech Hunter